ما هو علاج الخط الأول لداء كرون النشط من المتوسط إلى الشديد؟

References

1. In adult outpatients with moderate-to-severely active CD, the AGA recommends the use of infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab, or upadacitinib, over no treatment.
2. In adult outpatients with moderate-to-severely active CD, the AGA suggests the use of certolizumab pegol or vedolizumab, over no treatment.
3. In adult outpatients with moderate-to-severely active CD, the AGA SUGGESTS upfront use of advanced therapy compared with step-up therapy with initial use of corticosteroids and/or immunomodulator monotherapy.
4. In individuals with moderate-to-severely active CD in the ambulatory setting, induction and maintenance of clinical remission were considered critical, patient-centric outcomes for decision making.
5. CDAI scores <150 suggest clinical remission, and scores 150–220, 221–450, and >450 denote mild, moderate, and severe disease, respectively.